Phosphoinositide 3-kinase in Health and Disease [recurso electrónico] : Volume 2 / edited by Christian Rommel, Bart Vanhaesebroeck, Peter K. Vogt.
Tipo de material:
TextoSeries Current Topics in Microbiology and Immunology ; 347Editor: Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer, 2011Descripción: X, 306 p. online resourceTipo de contenido: text Tipo de medio: computer Tipo de portador: online resourceISBN: 9783642148163Tema(s): Medicine | Oncology | Biomedicine | Cancer ResearchFormatos físicos adicionales: Printed edition:: Sin títuloClasificación CDD: 614.5999 Clasificación LoC:RC261-271Recursos en línea: Libro electrónico
En: Springer eBooksResumen: From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here
| Tipo de ítem | Biblioteca actual | Colección | Signatura | Copia número | Estado | Fecha de vencimiento | Código de barras |
|---|---|---|---|---|---|---|---|
| Libro Electrónico | Biblioteca Electrónica | Colección de Libros Electrónicos | RC261 -271 (Browse shelf(Abre debajo)) | 1 | No para préstamo | 374866-2001 |
Navegando Biblioteca Electrónica Estantes, Código de colección: Colección de Libros Electrónicos Cerrar el navegador de estanterías (Oculta el navegador de estanterías)
| RC261 -271 Diverse Effects of Hypoxia on Tumor Progression | RC261 -271 Phosphoinositide 3-kinase in Health and Disease | RC261 -271 Cancer Immunology and Immunotherapy | RC261 -271 Phosphoinositide 3-kinase in Health and Disease | RC261 -271 NF-kB in Health and Disease | RC261 -271 Melanoma Development | RC261 -271 Methods of Cancer Diagnosis, Therapy, and Prognosis |
From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here
19
